Citi raised the firm’s price target on Quest Diagnostics (DGX) to $215 from $190 and keeps a Neutral rating on the shares.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Quest Diagnostics Signals Growth Amid Margin Pressures
- Quest Diagnostics price target raised to $220 from $215 at Jefferies
- Early notable gainers among liquid option names on February 10th
- Morning Movers: Fiserv and Spotify jump following fourth quarter results
- Quest Diagnostics Posts Strong 2025 Results, Boosts Shareholder Returns